STAT+: On Day 2 of JPM, Gilead lays outs it next test, a VC looks to raise funds, and one firm has FDA whiplash
This is the online version of The Readout, STAT’s flagship biotech newsletter. Sign up to get it in your inbox.
You’re back. We’re sort of back. It’s Day 2 of JPM and we’re definitely not exhausted or delirious yet.
This is Elaine Chen, Adam Feuerstein, Matt Herper, and Allison DeAngelis again. We’ve got a lot more news today, so let’s get to it.
The next test for Kite Pharma — and Gilead
It’s anito-cel, the CAR-T therapy for multiple myeloma that Gilead is developing in partnership with Arcellx. Gilead submitted the therapy to the FDA sometime before the end of December, Cindy Perettie, executive vice president of Kite Pharma, the cell therapy division of Gilead, told STAT at a Gilead media breakfast.
Matthew Herper, Elaine Chen, Allison DeAngelis, and Adam Feuerstein
Go to statnews